At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 55 target
Drug / intervention
GC511B CAR-T Cell Injectiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Early, First-in-Human, Investigator-Initiated, Open-label Study to Assess the Safety, Feasibility, Cytokinetics, and Preliminary Antitumor Activity of GC511B in Adult Trial Participants With DLL3+ Relapsed/Refractory Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences·interventional·Posted Nov 25, 2025·Updated May 1, 2026
In Brief
A Phase 1 clinical trial evaluating GC511B CAR-T Cell Injection for Relapsed/Refractory Small Cell Lung Cancer. Currently recruiting, targeting 55 participants across 2 sites.
Detailed Summary
This is a First-in-Human, open-label, early dose-escalation clinical study to evaluate the safety and preliminary efficacy of GC511B CAR T cell injection in Adult with DLL3+ r/r SCLC trial participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
CollaboratorsGracell Biotechnologies (Shanghai) Co., Ltd.
Timeline
Phase 1Recruiting
2026202720282029
First PostedNov 2025
Enrollment StartMar 2026
TodayJul 2026
Primary CompletionNov 2026
Study CompletionDec 2028
First PostedNov 25, 2025
Enrollment StartMar 3, 2026
Primary CompletionNov 10, 2026
Study CompletionDec 10, 2028
TodayJul 1, 2026
Enrollment to primary: 8 monthsPosted 7 months agoPrimary completion in 4 months
Interventions
GC511B CAR-T Cell Injectiondrug
This product is a lentiviral gene-modified autologous chimeric antigen receptor T-cell product that GC511B.Administration of GC511B CAR T-Cells a dose levels of DL1,DL2,DL3 and DL4 are administrated for each trial participants.Single IV infusion.